dc.contributor.author | Libertini, M | |
dc.contributor.author | Mitra, I | |
dc.contributor.author | van der Graaf, WTA | |
dc.contributor.author | Miah, AB | |
dc.contributor.author | Judson, I | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Thomas, K | |
dc.contributor.author | Moskovic, E | |
dc.contributor.author | Szucs, Z | |
dc.contributor.author | Benson, C | |
dc.contributor.author | Messiou, C | |
dc.date.accessioned | 2019-09-19T09:23:50Z | |
dc.date.issued | 2018-01 | |
dc.identifier.citation | Clinical sarcoma research, 2018, 8 pp. 13 - ? | |
dc.identifier.issn | 2045-3329 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3357 | |
dc.identifier.eissn | 2045-3329 | |
dc.identifier.doi | 10.1186/s13569-018-0100-3 | |
dc.description.abstract | Background One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports.Methods A retrospective database was used to identify consecutive patients diagnosed with aggressive fibromatosis (AF) and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at our tertiary referral centre between 2007 and 2014. MRI and symptom changes were recorded.Results Thirty-two patients (13 male 19 female, median age 41 years) were included. Median duration of treatment with tamoxifen was 316 days. Of 9 patients with progressive disease by RECIST 1.1 (28%): 4 patients experienced worsening symptoms; 3 patients had improved symptoms and 2 had no change in symptoms. Of 22 patients with stable disease (69%): 11 had no change in symptoms; 6 had improved symptoms and 5 patients had worsening symptoms. One patient achieved a partial response with improved symptoms.Conclusions No relationship was identified between symptomatic benefit and response by RECIST 1.1 on MRI. Prospective studies in AF should incorporate endpoints focusing on patient symptoms. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 13 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-04-04 | |
rioxxterms.versionofrecord | 10.1186/s13569-018-0100-3 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical sarcoma research | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 8 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | en_US |
dc.contributor.icrauthor | Judson, Ian | |
dc.contributor.icrauthor | Jones, Robin | |
dc.contributor.icrauthor | Messiou, Christina | |